1. Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia. (17th October 2014) Authors: Meers, S.; Selleslag, D.; Potier, H.; Glasmacher, A.; Mineur, P.; Voelter, V. Journal: Current medical research and opinion Issue: Volume 31:Number 1(2015:Jan.) Page Start: 35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia. (January 2015) Authors: Meers, S.; Selleslag, D.; Potier, H.; Glasmacher, A.; Mineur, P.; Voelter, V. Journal: Current medical research and opinion Issue: Volume 31:Number 1(2015:Jan.) Page Start: 35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey. Issue 1 (February 2015) Authors: Beguin, Y.; Selleslag, D.; Meers, S.; Graux, C.; Bries, G.; Deeren, D.; Vrelust, I.; Ravoet, C.; Theunissen, K.; Voelter, V.; Potier, H.; Trullemans, F.; Noens, L.; Mineur, P. Journal: Acta clinica belgica Issue: Volume 70:Issue 1(2015) Page Start: 34 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗